Impact of patient sample on costs of events in pharmacoeconomic models

Authors: Mullins, C Daniel; Subedi, Prasun R; Turk, Florian

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 8, Number 5, October 2008 , pp. 463-469(7)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Pharmacoeconomic guidelines have focused on improving the measurement of effectiveness, but have largely ignored the assessment of cost inputs. We explored differences in adverse event cost estimates derived from three different sources in a case study of selective COX2 NSAIDs. We found substantial differences in costs of adverse events across data sources. We also determined that treatment costs associated with adverse events differed substantially based upon inclusion/exclusion criteria. Health services researchers should be deliberate in the choice of adverse event treatment costs that are used in decision analytic models. Future guidelines should seek to delineate best practices for cost calculations.

Keywords: arthritis; cost measurement; healthcare cost; NSAID

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737167.8.5.463

Affiliations: 1: Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, 220 Arch Street, 12th Floor, Baltimore, MD 21202, USA., Email: dmullins@rx.umaryland.edu

Publication date: 2008-10-01

More about this publication?

Expert Review of Pharmacoeconomics & Outcomes Research provides expert commentary on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites